1987 related articles for article (PubMed ID: 22817889)
21. Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.
Wong SQ; Behren A; Mar VJ; Woods K; Li J; Martin C; Sheppard KE; Wolfe R; Kelly J; Cebon J; Dobrovic A; McArthur GA
Oncotarget; 2015 Jan; 6(2):1115-27. PubMed ID: 25544760
[TBL] [Abstract][Full Text] [Related]
22. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
[TBL] [Abstract][Full Text] [Related]
23. [Ultraviolet A-induced DNA damage: role in skin cancer].
Beani JC
Bull Acad Natl Med; 2014 Feb; 198(2):273-95. PubMed ID: 26263704
[TBL] [Abstract][Full Text] [Related]
24. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
26. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
[TBL] [Abstract][Full Text] [Related]
27. [Melanoma: from molecular studies to the treatment breakthrough].
Imianitov EN
Arkh Patol; 2013; 75(5):63-72. PubMed ID: 24341237
[TBL] [Abstract][Full Text] [Related]
28. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
Read J
Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
[TBL] [Abstract][Full Text] [Related]
30.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
31. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
32. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
33. Genomic and transcriptomic landscape of conjunctival melanoma.
Cisarova K; Folcher M; El Zaoui I; Pescini-Gobert R; Peter VG; Royer-Bertrand B; Zografos L; Schalenbourg A; Nicolas M; Rimoldi D; Leyvraz S; Riggi N; Moulin AP; Rivolta C
PLoS Genet; 2020 Dec; 16(12):e1009201. PubMed ID: 33383577
[TBL] [Abstract][Full Text] [Related]
34. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
35. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
36. Targeting effector pathways in RAC1
Uribe-Alvarez C; Guerrero-Rodríguez SL; Rhodes J; Cannon A; Chernoff J; Araiza-Olivera D
Small GTPases; 2021 Jul; 12(4):273-281. PubMed ID: 32043900
[TBL] [Abstract][Full Text] [Related]
37. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
38. Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting.
Vanni I; Pastorino L; Tanda ET; Andreotti V; Dalmasso B; Solari N; Mascherini M; Cabiddu F; Guadagno A; Coco S; Allavena E; Bruno W; Pietra G; Croce M; Gangemi R; Piana M; Zoppoli G; Ferrando L; Spagnolo F; Queirolo P; Ghiorzo P
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901733
[TBL] [Abstract][Full Text] [Related]
39. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev SI; Rimoldi D; Iseli C; Valsesia A; Robyr D; Gehrig C; Harshman K; Guipponi M; Bukach O; Zoete V; Michielin O; Muehlethaler K; Speiser D; Beckmann JS; Xenarios I; Halazonetis TD; Jongeneel CV; Stevenson BJ; Antonarakis SE
Nat Genet; 2011 Dec; 44(2):133-9. PubMed ID: 22197931
[TBL] [Abstract][Full Text] [Related]
40. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]